In the wake of the decision by Patrick Leahy to pull wide-ranging patent reform from the Senate Judiciary Committee’s agenda, there is a narrative emerging that it was all down to an unholy alliance of patent trolls, plaintiff lawyers and the pharmaceutical industry. Between them, so the story goes, they crushed a united front of technology companies to ensure that their own self-interest triumphed over the needs of America’s innovators, so ensuring continuing damage to the US economy.

Want to read more?

Register to access two of our subscriber-only articles per month

Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts

Already registered? Log in

What our customers are saying

One of the advantages of IAM is that it is high quality and yet still accessible and relevant to the non-specialist chief executives and senior managers who don't know what they don't know about IP. It's an important contribution to the upward IP education of senior managers.

Ian Harvey
Board member
International Intellectual Property Strategists Association (INTIPSA)


Subscribe to receive access to the full range of premium business intelligence, insights and analysis, as well as our IP directories, guides and daily news.

Why subscribe?